Vande Woude GF. Mechanism of met oncogene activation, Cell, vol.45, pp.895-904, 1986. ,
Molecular cloning and expression of human hepatocyte growth factor, Nature, vol.342, pp.440-443, 1989. ,
Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement, Proc Natl Acad Sci, vol.86, pp.5844-5848, 1989. ,
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility, Nature, vol.327, pp.239-242, 1987. ,
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition, Mol Cancer, vol.9, p.121, 2010. ,
Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase, Trends Cell Biol, vol.8, pp.404-410, 1998. ,
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family, Cell, vol.77, pp.261-271, 1994. ,
Motogenic and morphogenic activity of epithelial receptor tyrosine kinases, J Cell Biol, vol.133, pp.1095-1107, 1996. ,
How to make tubes: signaling by the Met receptor tyrosine kinase, Trends Cell Biol, vol.13, pp.328-335, 2003. ,
Targeting the hepatocyte growth factor-cMET axis in cancer therapy, Nat Rev Cancer, vol.30, pp.89-103, 2012. ,
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein, Mol Cell, vol.8, pp.995-1004, 2001. ,
SheddingGenerated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway, Traffic, vol.13, pp.1261-1272, 2012. ,
Vande Woude GF. Met, metastasis, motility and more, Nat Rev Mol Cell Biol, vol.4, pp.915-925, 2003. ,
Cell signaling by receptor tyrosine kinases, Cell, vol.141, pp.1117-1134, 2010. ,
Oncogenic kinase signalling, Nature, vol.411, pp.355-365, 2001. ,
DOI : 10.1038/35077225
Signal transduction by receptors with tyrosine kinase activity, Cell, vol.61, pp.203-212, 1990. ,
DOI : 10.1016/0092-8674(90)90801-k
Invasive growth: a METdriven genetic programme for cancer and stem cells, Nat Rev Cancer, vol.6, pp.637-645, 2006. ,
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480, Clin Genitourin Cancer, vol.4, pp.269-274, 2006. ,
The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas, Cancer, vol.85, pp.1894-1902, 1999. ,
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target, Oncol Rep, vol.25, pp.1517-1524, 2011. ,
High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer, J Thorac Oncol, vol.5, pp.305-313, 2010. ,
Activating mutations for the met tyrosine kinase receptor in human cancer, Proc Natl Acad Sci USA, vol.94, pp.11445-11450, 1997. ,
Two mutations affecting conserved residues in the Met receptor operate via different mechanisms, Oncogene, vol.19, pp.1354-1361, 2000. ,
cMET and phospho-cMET protein levels in breast cancers and survival outcomes, Clin Cancer Res, vol.18, pp.2269-2277, 2012. ,
Targeting MET Amplification as a New Oncogenic Driver, Cancers (Basel), vol.6, pp.1540-1552, 2014. ,
The multiple paths towards MET receptor addiction in cancer, Oncogene, 2018. ,
Tyrosine kinases as targets for cancer therapy, N Engl J Med, vol.353, pp.172-187, 2005. ,
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors, Cancer Res, vol.71, pp.1081-1091, 2011. ,
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors, Cancer Res, vol.70, pp.7580-7590, 2010. ,
Microenvironment and tumor cell plasticity: an easy way out, Cancer Lett, vol.341, pp.80-96, 2013. ,
Hypoxia-driven selection of the metastatic phenotype, Cancer Metastasis Rev, vol.26, pp.319-331, 2007. ,
, FEBS Lett, vol.581, pp.3582-3591, 2007.
Hypoxia and cancer, J Mol Med (Berl), vol.85, pp.1301-1307, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00319797
Hypoxia signalling controls metabolic demand, Curr Opin Cell Biol, vol.19, pp.223-229, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00319880
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science, vol.292, pp.464-68, 2001. ,
Targeting of HIF-alpha to the von HippelLindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, vol.292, pp.468-72, 2001. ,
Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha, J Biol Chem, vol.277, pp.40112-40117, 2002. ,
Targeting hypoxia in cancer therapy, Nat Rev Cancer, vol.11, pp.393-410, 2011. ,
Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis, Nature, vol.359, pp.843-845, 1992. ,
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis, Curr Top Microbiol Immunol, vol.237, pp.97-132, 1999. ,
Hypoxia-induced expression of phosducinlike 3 regulates expression of VEGFR-2 and promotes angiogenesis, Angiogenesis, vol.18, pp.449-62, 2015. ,
Oxygen-mediated endocytosis in cancer, J Cell Mol Med, vol.14, pp.496-503, 2010. ,
Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway, Int J Cancer, vol.119, pp.2750-2759, 2006. ,
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, vol.3, pp.347-361, 2003. ,
Cancer: Out of air is not out of action, Nature, vol.423, pp.593-595, 2003. ,
Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia, J Biol Chem, vol.289, pp.20448-20461, 2014. ,
A one-pot three-segment ligation strategy for protein chemical synthesis, Angew Chem Int Ed Engl, vol.51, pp.209-213, 2012. ,
Semi-synthesis of a HGF/SF kringle one (K1) domain scaffold generates a potent in vivo MET receptor agonist, Chem Sci, vol.6, pp.2110-2121, 2015. ,
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent, Proc Natl Acad Sci U S A, vol.110, pp.2987-2996, 2013. ,
Met degradation: more than one stone to shoot a receptor down, FASEB J, vol.26, pp.1387-1399, 2012. ,
Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension, Endocrinology, vol.146, pp.4682-4689, 2005. ,
Novel mechanism of action for hydralazine: induction of hypoxiainducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases, Circ Res, vol.95, pp.162-169, 2004. ,
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation, Cell, vol.107, pp.43-54, 2001. ,
URL : https://hal.archives-ouvertes.fr/in2p3-00023372
Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis, Curr Drug Targets, vol.9, pp.422-435, 2008. ,
Role of protein-phosphorylation events in the anoxia signaltransduction pathway leading to the inhibition of total protein synthesis in isolated hepatocytes, Eur J Biochem, vol.249, pp.121-126, 1997. ,
Repression of heme oxygenase-1 by hypoxia in vascular endothelial cells, Biochem Biophys Res Commun, vol.271, pp.665-671, 2000. ,
Gastrointestinal malignancies harbor actionable MET exon 14 deletions, Oncotarget, vol.6, pp.28211-28233, 2015. ,
Downregulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis, Mol Biol Cell, vol.20, pp.2495-507, 2009. ,
Gene of the month: MET, J Clin Pathol, vol.68, pp.405-409, 2015. ,
Thirty years of research on met receptor to move a biomarker from bench to bedside, Cancer Res, vol.74, pp.6737-6744, 2014. ,
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase, Mol Cell Biol, vol.20, pp.8513-8525, 2000. ,
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1, J Biol Chem, vol.278, pp.5728-5735, 2003. ,
Regulation of the Met receptortyrosine kinase by the protein-tyrosine phosphatase 1B, T-cell phosphatase, J Biol Chem, vol.283, pp.34374-34383, 2008. ,
Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases, Am J Respir Crit Care Med, vol.183, pp.1092-1102, 2011. ,
Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain, Sci Rep, vol.7, p.9000, 2017. ,
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature, vol.379, pp.88-91, 1996. ,
Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res, vol.62, pp.3387-3394, 2002. ,
Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, vol.159, pp.166-177, 2015. ,
Mediation of the DCC apoptotic signal by DIP13 alpha, J Biol Chem, vol.277, pp.26281-26285, 2002. ,
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis, Dev Biol, vol.308, pp.44-53, 2007. ,
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma, Proc Natl Acad Sci USA, vol.109, pp.570-575, 2012. ,
DOI : 10.1073/pnas.1119059109
URL : http://www.pnas.org/content/109/2/570.full.pdf
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors, Cancer Discov, vol.5, pp.850-59, 2015. ,
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov, vol.5, pp.842-891, 2015. ,
DOI : 10.1158/2159-8290.cd-14-1467
URL : http://cancerdiscovery.aacrjournals.org/content/5/8/842.full.pdf
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification, J Thorac Oncol, vol.6, pp.942-946, 2011. ,